{
 "cells": [
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Build graph from patients similarity\n",
    "In this notebook, we test some methods to build the graph from an initial dataframe."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "from models.BuildGraph import BuildGraph\n",
    "from utils.preProcessing import preProcessing"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "preprocessor = preProcessing()"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 1. Reading dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Anonymous ID</th>\n",
       "      <th>EGA ID</th>\n",
       "      <th>Tumour type</th>\n",
       "      <th>Sex</th>\n",
       "      <th>Line of therapy</th>\n",
       "      <th>Immunotherapy regimen</th>\n",
       "      <th>Cohort</th>\n",
       "      <th>Reason for discontinuation</th>\n",
       "      <th>Best response</th>\n",
       "      <th>Age at advanced disease diagnosis</th>\n",
       "      <th>...</th>\n",
       "      <th>Alive_0</th>\n",
       "      <th>Time to progression (days)</th>\n",
       "      <th>Progression_1</th>\n",
       "      <th>Clinical benefit</th>\n",
       "      <th>CD8+ T cell score</th>\n",
       "      <th>Exome mut per mb</th>\n",
       "      <th>Genome mut per mb</th>\n",
       "      <th>CD274 expression</th>\n",
       "      <th>M1M2 expression</th>\n",
       "      <th>Lymph related</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>14891</td>\n",
       "      <td>EGAD00001001961</td>\n",
       "      <td>LUNG</td>\n",
       "      <td>F</td>\n",
       "      <td>8</td>\n",
       "      <td>Nivolumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Progression</td>\n",
       "      <td>Mixed</td>\n",
       "      <td>45</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>179</td>\n",
       "      <td>1</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.351869</td>\n",
       "      <td>11.095310</td>\n",
       "      <td>23.0729</td>\n",
       "      <td>4.1689</td>\n",
       "      <td>55.51575</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>18624</td>\n",
       "      <td>EGAD00001002047</td>\n",
       "      <td>AECA</td>\n",
       "      <td>F</td>\n",
       "      <td>10</td>\n",
       "      <td>Nivolumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Progression</td>\n",
       "      <td>Stable disease</td>\n",
       "      <td>47</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>148</td>\n",
       "      <td>1</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.071464</td>\n",
       "      <td>3.876336</td>\n",
       "      <td>5.4552</td>\n",
       "      <td>0.7910</td>\n",
       "      <td>9.32352</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>21392</td>\n",
       "      <td>EGAD00001002544</td>\n",
       "      <td>OV</td>\n",
       "      <td>F</td>\n",
       "      <td>6</td>\n",
       "      <td>Monalizumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Progression</td>\n",
       "      <td>Physician assessed SD</td>\n",
       "      <td>57</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>79</td>\n",
       "      <td>1</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.040394</td>\n",
       "      <td>2.415688</td>\n",
       "      <td>4.1274</td>\n",
       "      <td>4.0377</td>\n",
       "      <td>50.12008</td>\n",
       "      <td>Lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>21516</td>\n",
       "      <td>EGAD00001002546</td>\n",
       "      <td>SKCM</td>\n",
       "      <td>F</td>\n",
       "      <td>3</td>\n",
       "      <td>Ipilimumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Death</td>\n",
       "      <td>Not evaluable</td>\n",
       "      <td>29</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>11</td>\n",
       "      <td>0</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.052774</td>\n",
       "      <td>6.235845</td>\n",
       "      <td>11.4871</td>\n",
       "      <td>0.6006</td>\n",
       "      <td>1.58550</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>22186</td>\n",
       "      <td>EGAD00001001966</td>\n",
       "      <td>LUNG</td>\n",
       "      <td>F</td>\n",
       "      <td>4</td>\n",
       "      <td>Atezolizumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Progression</td>\n",
       "      <td>Stable disease</td>\n",
       "      <td>52</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>80</td>\n",
       "      <td>1</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.009323</td>\n",
       "      <td>4.606660</td>\n",
       "      <td>7.1503</td>\n",
       "      <td>1.8234</td>\n",
       "      <td>38.42695</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>92</th>\n",
       "      <td>39280</td>\n",
       "      <td>EGAD00001004933</td>\n",
       "      <td>LUNG</td>\n",
       "      <td>M</td>\n",
       "      <td>2</td>\n",
       "      <td>Pembrolizumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Toxicity</td>\n",
       "      <td>Physician Assessed SD</td>\n",
       "      <td>60</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>401</td>\n",
       "      <td>0</td>\n",
       "      <td>DCB</td>\n",
       "      <td>0.695396</td>\n",
       "      <td>84.998501</td>\n",
       "      <td>96.4079</td>\n",
       "      <td>8.4768</td>\n",
       "      <td>86.62561</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>94</th>\n",
       "      <td>37899</td>\n",
       "      <td>EGAD00001005838</td>\n",
       "      <td>CHOL</td>\n",
       "      <td>F</td>\n",
       "      <td>2</td>\n",
       "      <td>Nivolumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Death</td>\n",
       "      <td>Physician assessed PR</td>\n",
       "      <td>38</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>96</td>\n",
       "      <td>0</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.818233</td>\n",
       "      <td>2.247151</td>\n",
       "      <td>2.7416</td>\n",
       "      <td>11.2704</td>\n",
       "      <td>47.97376</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>95</th>\n",
       "      <td>37775</td>\n",
       "      <td>EGAD00001004934</td>\n",
       "      <td>HNSC</td>\n",
       "      <td>M</td>\n",
       "      <td>1</td>\n",
       "      <td>Avelumab/OX40 agonist PF-04518600</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Progression</td>\n",
       "      <td>Stable disease</td>\n",
       "      <td>69</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>69</td>\n",
       "      <td>1</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.018982</td>\n",
       "      <td>3.848247</td>\n",
       "      <td>5.8036</td>\n",
       "      <td>8.7136</td>\n",
       "      <td>5.13403</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>96</th>\n",
       "      <td>38313</td>\n",
       "      <td>EGAD00001005844</td>\n",
       "      <td>ACC</td>\n",
       "      <td>F</td>\n",
       "      <td>3</td>\n",
       "      <td>Avelumab/Debio1143 (SMAC mimetic)</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Toxicity</td>\n",
       "      <td>Partial response</td>\n",
       "      <td>34</td>\n",
       "      <td>...</td>\n",
       "      <td>1</td>\n",
       "      <td>51</td>\n",
       "      <td>1</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>5.617878</td>\n",
       "      <td>7.7940</td>\n",
       "      <td>0.0688</td>\n",
       "      <td>0.51364</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>97</th>\n",
       "      <td>38207</td>\n",
       "      <td>EGAD00001005850</td>\n",
       "      <td>LUNG</td>\n",
       "      <td>F</td>\n",
       "      <td>1</td>\n",
       "      <td>Pembrolizumab</td>\n",
       "      <td>Naive</td>\n",
       "      <td>Progression</td>\n",
       "      <td>Physician assessed SD</td>\n",
       "      <td>50</td>\n",
       "      <td>...</td>\n",
       "      <td>0</td>\n",
       "      <td>104</td>\n",
       "      <td>1</td>\n",
       "      <td>NCB</td>\n",
       "      <td>0.110416</td>\n",
       "      <td>33.763449</td>\n",
       "      <td>53.2769</td>\n",
       "      <td>23.8818</td>\n",
       "      <td>11.22022</td>\n",
       "      <td>Non-lymph related</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>82 rows × 21 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "    Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       "0          14891  EGAD00001001961        LUNG   F               8  \\\n",
       "1          18624  EGAD00001002047        AECA   F              10   \n",
       "2          21392  EGAD00001002544          OV   F               6   \n",
       "3          21516  EGAD00001002546        SKCM   F               3   \n",
       "4          22186  EGAD00001001966        LUNG   F               4   \n",
       "..           ...              ...         ...  ..             ...   \n",
       "92         39280  EGAD00001004933        LUNG   M               2   \n",
       "94         37899  EGAD00001005838        CHOL   F               2   \n",
       "95         37775  EGAD00001004934        HNSC   M               1   \n",
       "96         38313  EGAD00001005844         ACC   F               3   \n",
       "97         38207  EGAD00001005850        LUNG   F               1   \n",
       "\n",
       "                Immunotherapy regimen Cohort Reason for discontinuation   \n",
       "0                           Nivolumab  Naive                Progression  \\\n",
       "1                           Nivolumab  Naive                Progression   \n",
       "2                         Monalizumab  Naive                Progression   \n",
       "3                          Ipilimumab  Naive                      Death   \n",
       "4                        Atezolizumab  Naive                Progression   \n",
       "..                                ...    ...                        ...   \n",
       "92                      Pembrolizumab  Naive                   Toxicity   \n",
       "94                          Nivolumab  Naive                      Death   \n",
       "95  Avelumab/OX40 agonist PF-04518600  Naive                Progression   \n",
       "96  Avelumab/Debio1143 (SMAC mimetic)  Naive                   Toxicity   \n",
       "97                      Pembrolizumab  Naive                Progression   \n",
       "\n",
       "            Best response  Age at advanced disease diagnosis  ...  Alive_0   \n",
       "0                   Mixed                                 45  ...        1  \\\n",
       "1          Stable disease                                 47  ...        1   \n",
       "2   Physician assessed SD                                 57  ...        1   \n",
       "3           Not evaluable                                 29  ...        1   \n",
       "4          Stable disease                                 52  ...        1   \n",
       "..                    ...                                ...  ...      ...   \n",
       "92  Physician Assessed SD                                 60  ...        1   \n",
       "94  Physician assessed PR                                 38  ...        1   \n",
       "95         Stable disease                                 69  ...        1   \n",
       "96       Partial response                                 34  ...        1   \n",
       "97  Physician assessed SD                                 50  ...        0   \n",
       "\n",
       "    Time to progression (days)  Progression_1  Clinical benefit   \n",
       "0                          179              1               NCB  \\\n",
       "1                          148              1               NCB   \n",
       "2                           79              1               NCB   \n",
       "3                           11              0               NCB   \n",
       "4                           80              1               NCB   \n",
       "..                         ...            ...               ...   \n",
       "92                         401              0               DCB   \n",
       "94                          96              0               NCB   \n",
       "95                          69              1               NCB   \n",
       "96                          51              1               NCB   \n",
       "97                         104              1               NCB   \n",
       "\n",
       "   CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       "0           0.351869         11.095310            23.0729            4.1689  \\\n",
       "1           0.071464          3.876336             5.4552            0.7910   \n",
       "2           0.040394          2.415688             4.1274            4.0377   \n",
       "3           0.052774          6.235845            11.4871            0.6006   \n",
       "4           0.009323          4.606660             7.1503            1.8234   \n",
       "..               ...               ...                ...               ...   \n",
       "92          0.695396         84.998501            96.4079            8.4768   \n",
       "94          0.818233          2.247151             2.7416           11.2704   \n",
       "95          0.018982          3.848247             5.8036            8.7136   \n",
       "96          0.000000          5.617878             7.7940            0.0688   \n",
       "97          0.110416         33.763449            53.2769           23.8818   \n",
       "\n",
       "    M1M2 expression      Lymph related  \n",
       "0          55.51575  Non-lymph related  \n",
       "1           9.32352  Non-lymph related  \n",
       "2          50.12008      Lymph related  \n",
       "3           1.58550  Non-lymph related  \n",
       "4          38.42695  Non-lymph related  \n",
       "..              ...                ...  \n",
       "92         86.62561  Non-lymph related  \n",
       "94         47.97376  Non-lymph related  \n",
       "95          5.13403  Non-lymph related  \n",
       "96          0.51364  Non-lymph related  \n",
       "97         11.22022  Non-lymph related  \n",
       "\n",
       "[82 rows x 21 columns]"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.read_excel('data/Supplemental-table1.xlsx')\n",
    "df = df.loc[df[\"Cohort\"] == \"Naive\"]\n",
    "df"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 2. Find nearest patients\n",
    "The useful features to evaluate patients similarity are :\n",
    "- Tumour type\n",
    "- Sex\n",
    "- Immunotherapy regimen\n",
    "- Age\n",
    "- CD8+ T cell score\n",
    "- M1M2 expression score\n",
    "- Genome mut per mb\n",
    "- Exome mut per mb\n",
    "- CD274 expression\n",
    "\n",
    "Some of these features are categorical, so we need to numerize them."
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### a. Numerize categorical features and normalization"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "df_numerized = pd.get_dummies(df.loc[:,[\"Tumour type\",\"Sex\",\"Immunotherapy regimen\",\"Age at advanced disease diagnosis\",\"CD8+ T cell score\",\"M1M2 expression\",\"Genome mut per mb\",\"Exome mut per mb\",\"CD274 expression\"]]).astype(float)\n",
    "X_numerized = preprocessor.normalize_data(df_numerized.to_numpy())"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### b. Compute adjacency matrix"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "# 1 neighbor per patient, and euclidean distance\n",
    "buildgraph = BuildGraph(n_neighbors=2, metric=\"euclidean\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "array([[1., 0., 0., ..., 0., 0., 0.],\n",
       "       [0., 1., 0., ..., 0., 0., 0.],\n",
       "       [0., 0., 1., ..., 0., 0., 0.],\n",
       "       ...,\n",
       "       [0., 0., 0., ..., 1., 0., 0.],\n",
       "       [0., 0., 0., ..., 0., 1., 0.],\n",
       "       [0., 0., 0., ..., 0., 0., 1.]])"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "A = buildgraph.build_adjacency_matrix(X_numerized)\n",
    "A"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 3. Split per tumour type"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "tumour_types = np.unique(df[\"Tumour type\"].to_numpy())\n",
    "dico_tumour = {} #clé : tumour type, value = df_associated\n",
    "for i in range(tumour_types.shape[0]):\n",
    "    dico_tumour[tumour_types[i]] = df.loc[df[\"Tumour type\"] == tumour_types[i]]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'ACC':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 33         28123  EGAD00001003065         ACC   M               2  \\\n",
       " 96         38313  EGAD00001005844         ACC   F               3   \n",
       " \n",
       "                 Immunotherapy regimen Cohort Reason for discontinuation   \n",
       " 33           Tremelimumab, Durvalumab  Naive                Progression  \\\n",
       " 96  Avelumab/Debio1143 (SMAC mimetic)  Naive                   Toxicity   \n",
       " \n",
       "           Best response  Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 33  Progressive disease                                 40  ...        0  \\\n",
       " 96     Partial response                                 34  ...        1   \n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 33                         107              1               NCB  \\\n",
       " 96                          51              1               NCB   \n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 33          0.068854          0.702235             0.7638            0.7885  \\\n",
       " 96          0.000000          5.617878             7.7940            0.0688   \n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 33          7.71459  Non-lymph related  \n",
       " 96          0.51364  Non-lymph related  \n",
       " \n",
       " [2 rows x 21 columns],\n",
       " 'AECA':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 1          18624  EGAD00001002047        AECA   F              10  \\\n",
       " 42         28430  EGAD00001003085        AECA   F               1   \n",
       " \n",
       "    Immunotherapy regimen Cohort Reason for discontinuation   \n",
       " 1              Nivolumab  Naive                Progression  \\\n",
       " 42         Pembrolizumab  Naive                Progression   \n",
       " \n",
       "           Best response  Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 1        Stable disease                                 47  ...        1  \\\n",
       " 42  Progressive disease                                 55  ...        1   \n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 1                          148              1               NCB  \\\n",
       " 42                          61              1               NCB   \n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 1           0.071464          3.876336             5.4552             0.791  \\\n",
       " 42          0.071885          1.657274             1.8075             2.178   \n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 1           9.32352  Non-lymph related  \n",
       " 42          7.11986      Lymph related  \n",
       " \n",
       " [2 rows x 21 columns],\n",
       " 'BRCA':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 11         23701  EGAD00001002576        BRCA   F               7  \\\n",
       " 24         25980  EGAD00001002997        BRCA   F               5   \n",
       " 29         26376  EGAD00001003016        BRCA   F               5   \n",
       " 32         27388  EGAD00001003042        BRCA   F               2   \n",
       " 37         28178  EGAD00001003072        BRCA   F               3   \n",
       " 45         30221  EGAD00001003607        BRCA   F               1   \n",
       " 46         30313  EGAD00001003670        BRCA   F               3   \n",
       " 49         31031  EGAD00001003720        BRCA   F               4   \n",
       " 54         31042  EGAD00001003675        BRCA   F               5   \n",
       " 60         32015  EGAD00001003714        BRCA   F               5   \n",
       " 64         33532  EGAD00001004623        BRCA   F               6   \n",
       " 67         34121  EGAD00001004632        BRCA   F               6   \n",
       " \n",
       "                                 Immunotherapy regimen Cohort   \n",
       " 11  GEMCITABINE, VINORELBINE, PEMBROLIZUMAB (ARIZONA)  Naive  \\\n",
       " 24                                      Pembrolizumab  Naive   \n",
       " 29                                       Atezolizumab  Naive   \n",
       " 32                              OX40 agonist MOXR0916  Naive   \n",
       " 37                                      Pembrolizumab  Naive   \n",
       " 45                                      Pembrolizumab  Naive   \n",
       " 46                                       Atezolizumab  Naive   \n",
       " 49                            TRASTUZUMAB, DURVALUMAB  Naive   \n",
       " 54                                Nivolumab/anti-LAG3  Naive   \n",
       " 60                                      Pembrolizumab  Naive   \n",
       " 64  NIVOLUMAB (P1T986205),BMS-986205 (P1T986205)/I...  Naive   \n",
       " 67  BMS-986205 (P1T986205)/IDO1 inhibitor + nivolumab  Naive   \n",
       " \n",
       "    Reason for discontinuation          Best response   \n",
       " 11          Progression/death    Progressive disease  \\\n",
       " 24                Progression       Partial response   \n",
       " 29                Progression    Progressive disease   \n",
       " 32                Progression  Physician assessed PD   \n",
       " 37                Progression    Progressive disease   \n",
       " 45                Progression    Progressive disease   \n",
       " 46                Progression         Stable disease   \n",
       " 49                Progression    Progressive disease   \n",
       " 54                Progression    Progressive disease   \n",
       " 60                    Ongoing  Physician assessed SD   \n",
       " 64                Progression         Stable disease   \n",
       " 67                Progression    Progressive disease   \n",
       " \n",
       "     Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 11                                 30  ...        1  \\\n",
       " 24                                 59  ...        1   \n",
       " 29                                 46  ...        1   \n",
       " 32                                 39  ...        1   \n",
       " 37                                 42  ...        1   \n",
       " 45                                 53  ...        1   \n",
       " 46                                 65  ...        1   \n",
       " 49                                 49  ...        1   \n",
       " 54                                 56  ...        1   \n",
       " 60                                 59  ...        0   \n",
       " 64                                 68  ...        0   \n",
       " 67                                 54  ...        1   \n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 11                          73              1               NCB  \\\n",
       " 24                         214              1               DCB   \n",
       " 29                          34              1               NCB   \n",
       " 32                          55              1               NCB   \n",
       " 37                          57              1               NCB   \n",
       " 45                         110              1               NCB   \n",
       " 46                         167              1               NCB   \n",
       " 49                          36              1               NCB   \n",
       " 54                          51              1               NCB   \n",
       " 60                         626              0               DCB   \n",
       " 64                         124              1               NCB   \n",
       " 67                          80              1               NCB   \n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 11          0.000000          5.617878           7.047600            0.9796  \\\n",
       " 24          0.126651          6.853812           9.394100            3.0892   \n",
       " 29          0.046495          4.915644           3.864900            1.8084   \n",
       " 32          0.037288          3.567353           3.599200            0.5864   \n",
       " 37          0.067498          2.499956           2.901100            1.1085   \n",
       " 45          0.165046          6.853812           7.326600            0.6363   \n",
       " 46          0.193522          4.971822           2.089324            1.9805   \n",
       " 49          0.109643          7.134706           8.342000            1.5074   \n",
       " 54          0.131732          7.247063           6.846600            1.1146   \n",
       " 60          0.196923         20.112005          22.145100            1.6111   \n",
       " 64          0.042727          5.084180           5.905200            0.8302   \n",
       " 67          0.001344          6.909990           8.335400            1.0353   \n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 11          7.78044  Non-lymph related  \n",
       " 24         36.90372  Non-lymph related  \n",
       " 29         19.18773  Non-lymph related  \n",
       " 32          2.37295      Lymph related  \n",
       " 37         20.74176  Non-lymph related  \n",
       " 45         13.93909      Lymph related  \n",
       " 46         14.97239  Non-lymph related  \n",
       " 49         20.86179  Non-lymph related  \n",
       " 54         28.99290      Lymph related  \n",
       " 60         18.93014      Lymph related  \n",
       " 64          8.82845  Non-lymph related  \n",
       " 67          3.66514  Non-lymph related  \n",
       " \n",
       " [12 rows x 21 columns],\n",
       " 'CHOL':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 78         36069  EGAD00001004657        CHOL   F               6  \\\n",
       " 86         37970  EGAD00001004706        CHOL   M               2   \n",
       " 94         37899  EGAD00001005838        CHOL   F               2   \n",
       " \n",
       "        Immunotherapy regimen Cohort Reason for discontinuation   \n",
       " 78                 Nivolumab  Naive                      Death  \\\n",
       " 86  Tremelimumab, Durvalumab  Naive                Progression   \n",
       " 94                 Nivolumab  Naive                      Death   \n",
       " \n",
       "             Best response  Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 78          Not evaluable                                 70  ...        1  \\\n",
       " 86    Progressive disease                                 59  ...        1   \n",
       " 94  Physician assessed PR                                 38  ...        1   \n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 78                          34              0               NCB  \\\n",
       " 86                          82              1               NCB   \n",
       " 94                          96              0               NCB   \n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 78          0.086178          9.747019            11.4801            3.0023  \\\n",
       " 86          0.128224          1.825810             2.5119            3.6020   \n",
       " 94          0.818233          2.247151             2.7416           11.2704   \n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 78         16.17461  Non-lymph related  \n",
       " 86         15.86816  Non-lymph related  \n",
       " 94         47.97376  Non-lymph related  \n",
       " \n",
       " [3 rows x 21 columns],\n",
       " 'COLO':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 10         23674  EGAD00001001876        COLO   F               7  \\\n",
       " 16         25419  EGAD00001002611        COLO   M               2   \n",
       " 19         25589  EGAD00001002628        COLO   F               4   \n",
       " 44         29146  EGAD00001003647        COLO   M               4   \n",
       " 66         33480  EGAD00001004622        COLO   F               3   \n",
       " 80         37080  EGAD00001004677        COLO   M               4   \n",
       " \n",
       "                Immunotherapy regimen Cohort Reason for discontinuation   \n",
       " 10              Ipilimumab/nivolumab  Naive                   Toxicity  \\\n",
       " 16                      Atezolizumab  Naive                Progression   \n",
       " 19                         Nivolumab  Naive                Progression   \n",
       " 44                     Pembrolizumab  Naive                      Death   \n",
       " 66  TREMELIMUMAB,DURVALUMAB (GIC026)  Naive                Progression   \n",
       " 80          Tremelimumab, Durvalumab  Naive                Progression   \n",
       " \n",
       "             Best response  Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 10  Physician assessed PR                                 65  ...        0  \\\n",
       " 16    Progressive disease                                 48  ...        1   \n",
       " 19  Physician assessed PR                                 55  ...        1   \n",
       " 44          Not evaluable                                 59  ...        1   \n",
       " 66    Progressive disease                                 52  ...        1   \n",
       " 80    Progressive disease                                 69  ...        1   \n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 10                         184              0               DCB  \\\n",
       " 16                          41              1               NCB   \n",
       " 19                         204              1               DCB   \n",
       " 44                          21              1               NCB   \n",
       " 66                          55              1               NCB   \n",
       " 80                          83              1               NCB   \n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 10          0.202788         80.953628           107.1840            1.7444  \\\n",
       " 16          0.085451          2.724671             4.3225            2.3061   \n",
       " 19          0.139384         16.348026            16.0194           25.7392   \n",
       " 44          0.025013         43.201485            46.1567            0.6936   \n",
       " 66          0.180464          4.438124             7.4348            1.8472   \n",
       " 80          0.071239          3.483085             4.6991            0.7738   \n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 10         19.27326  Non-lymph related  \n",
       " 16         10.39606  Non-lymph related  \n",
       " 19         23.19457  Non-lymph related  \n",
       " 44          5.06493  Non-lymph related  \n",
       " 66         19.51125  Non-lymph related  \n",
       " 80          2.70301  Non-lymph related  \n",
       " \n",
       " [6 rows x 21 columns],\n",
       " 'ESCA':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 34         28125  EGAD00001003067        ESCA   M               4  \\\n",
       " \n",
       "    Immunotherapy regimen Cohort Reason for discontinuation   \n",
       " 34         Pembrolizumab  Naive                Progression  \\\n",
       " \n",
       "             Best response  Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 34  Physician assessed PD                                 26  ...        1  \\\n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 34                          57              1               NCB  \\\n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 34           0.05436          5.589789             8.0669            4.0959  \\\n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 34          6.19952  Non-lymph related  \n",
       " \n",
       " [1 rows x 21 columns],\n",
       " 'GCT':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 21         25604  EGAD00001002632         GCT   M               5  \\\n",
       " \n",
       "    Immunotherapy regimen Cohort Reason for discontinuation   Best response   \n",
       " 21          Atezolizumab  Naive                Progression  Stable disease  \\\n",
       " \n",
       "     Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 21                                 26  ...        1  \\\n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 21                         102              1               NCB  \\\n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 21          0.016645          3.202191             5.2737            0.1595  \\\n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 21          1.29605  Non-lymph related  \n",
       " \n",
       " [1 rows x 21 columns],\n",
       " 'HNSC':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 56         32395  EGAD00001003734        HNSC   M               1  \\\n",
       " 58         31980  EGAD00001003716        HNSC   M               1   \n",
       " 76         36067  EGAD00001004655        HNSC   M               4   \n",
       " 95         37775  EGAD00001004934        HNSC   M               1   \n",
       " \n",
       "                 Immunotherapy regimen Cohort Reason for discontinuation   \n",
       " 56                      Pembrolizumab  Naive                      Death  \\\n",
       " 58                      Pembrolizumab  Naive                Progression   \n",
       " 76           Tremelimumab, Durvalumab  Naive                Progression   \n",
       " 95  Avelumab/OX40 agonist PF-04518600  Naive                Progression   \n",
       " \n",
       "             Best response  Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 56          Not evaluable                                 71  ...        1  \\\n",
       " 58  Physician assessed PD                                 77  ...        1   \n",
       " 76    Progressive disease                                 56  ...        1   \n",
       " 95         Stable disease                                 69  ...        1   \n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 56                          60              0               NCB  \\\n",
       " 58                         167              1               NCB   \n",
       " 76                          43              1               NCB   \n",
       " 95                          69              1               NCB   \n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 56          0.132237         62.948328            96.0990            3.5241  \\\n",
       " 58          0.505999          4.859465             5.9303            7.5227   \n",
       " 76          0.080266          7.836940             7.5363            4.7923   \n",
       " 95          0.018982          3.848247             5.8036            8.7136   \n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 56          3.44891  Non-lymph related  \n",
       " 58         55.99228  Non-lymph related  \n",
       " 76         11.43672  Non-lymph related  \n",
       " 95          5.13403  Non-lymph related  \n",
       " \n",
       " [4 rows x 21 columns],\n",
       " 'KDNY':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 70         34159  EGAD00001004633        KDNY   M               2  \\\n",
       " 77         37093  EGAD00001003722        KDNY   M               2   \n",
       " \n",
       "    Immunotherapy regimen Cohort Reason for discontinuation   \n",
       " 70             Nivolumab  Naive                Progression  \\\n",
       " 77             Nivolumab  Naive                Progression   \n",
       " \n",
       "             Best response  Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 70  Physician assessed PR                                 47  ...        0  \\\n",
       " 77  Physician assessed PD                                 27  ...        1   \n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 70                         369              1               DCB  \\\n",
       " 77                          51              1               NCB   \n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 70          0.084295          1.825810             2.4997            1.1784  \\\n",
       " 77          0.000000          2.022436             2.4881            7.4637   \n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 70         11.15613      Lymph related  \n",
       " 77          1.80935  Non-lymph related  \n",
       " \n",
       " [2 rows x 21 columns],\n",
       " 'LUNG':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 0          14891  EGAD00001001961        LUNG   F               8  \\\n",
       " 4          22186  EGAD00001001966        LUNG   F               4   \n",
       " 6          40507  EGAD00001005877        LUNG   F               1   \n",
       " 9          23237  EGAD00001002564        LUNG   F               4   \n",
       " 18         25593  EGAD00001004596        LUNG   F               4   \n",
       " 20         28132  EGAD00001004903        LUNG   M               2   \n",
       " 23         25921  EGAD00001002646        LUNG   M               3   \n",
       " 25         25966  EGAD00001003617        LUNG   F               3   \n",
       " 26         26016  EGAD00001003005        LUNG   F               3   \n",
       " 28         26123  EGAD00001003011        LUNG   M               3   \n",
       " 40         28278  EGAD00001003076        LUNG   F               3   \n",
       " 41         28495  EGAD00001003639        LUNG   F               2   \n",
       " 43         28668  EGAD00001003650        LUNG   M               3   \n",
       " 51         30897  EGAD00001003657        LUNG   M               2   \n",
       " 52         30822  EGAD00001003661        LUNG   F               3   \n",
       " 53         31034  EGAD00001003694        LUNG   M               2   \n",
       " 61         32558  EGAD00001003717        LUNG   M               2   \n",
       " 71         35337  EGAD00001004650        LUNG   M               2   \n",
       " 72         35258  EGAD00001004644        LUNG   M               2   \n",
       " 79         36962  EGAD00001004669        LUNG   F               1   \n",
       " 82         37027  EGAD00001004673        LUNG   F               3   \n",
       " 83         37719  EGAD00001004693        LUNG   F               3   \n",
       " 85         37717  EGAD00001004692        LUNG   F               4   \n",
       " 92         39280  EGAD00001004933        LUNG   M               2   \n",
       " 97         38207  EGAD00001005850        LUNG   F               1   \n",
       " \n",
       "                                 Immunotherapy regimen Cohort   \n",
       " 0                                           Nivolumab  Naive  \\\n",
       " 4                                        Atezolizumab  Naive   \n",
       " 6                                       Pembrolizumab  Naive   \n",
       " 9                                           Nivolumab  Naive   \n",
       " 18  Tremelimumab, Durvalumab, Pemetrexed, Carboplatin  Naive   \n",
       " 20                                          Nivolumab  Naive   \n",
       " 23                                          Nivolumab  Naive   \n",
       " 25                                          Nivolumab  Naive   \n",
       " 26                                          Nivolumab  Naive   \n",
       " 28                                          Nivolumab  Naive   \n",
       " 40                                          Nivolumab  Naive   \n",
       " 41                                          Nivolumab  Naive   \n",
       " 43                                          Nivolumab  Naive   \n",
       " 51                           Tremelimumab, Durvalumab  Naive   \n",
       " 52                                          Nivolumab  Naive   \n",
       " 53                                          Nivolumab  Naive   \n",
       " 61                                          Nivolumab  Naive   \n",
       " 71                                          Nivolumab  Naive   \n",
       " 72                                          Nivolumab  Naive   \n",
       " 79                           Tremelimumab, Durvalumab  Naive   \n",
       " 82                                          Nivolumab  Naive   \n",
       " 83                                          Nivolumab  Naive   \n",
       " 85                                          Nivolumab  Naive   \n",
       " 92                                      Pembrolizumab  Naive   \n",
       " 97                                      Pembrolizumab  Naive   \n",
       " \n",
       "    Reason for discontinuation          Best response   \n",
       " 0                 Progression                  Mixed  \\\n",
       " 4                 Progression         Stable disease   \n",
       " 6                 Progression  Physician assessed PD   \n",
       " 9                    Toxicity          Not evaluable   \n",
       " 18                Progression       Partial response   \n",
       " 20                Progression  Physician assessed PD   \n",
       " 23                Progression  Physician assessed PR   \n",
       " 25                Progression  Physician assessed SD   \n",
       " 26                Progression  Physician assessed PD   \n",
       " 28                Progression          Not evaluable   \n",
       " 40                   Toxicity  Physician assessed SD   \n",
       " 41                      Death  Physician assessed PR   \n",
       " 43                Progression  Physician assessed PD   \n",
       " 51                Progression         Stable disease   \n",
       " 52                      Death          Not evaluable   \n",
       " 53                   Toxicity  Physician assessed PR   \n",
       " 61                Progression  Physician assessed PD   \n",
       " 71                Progression  Physician assessed SD   \n",
       " 72                      Death          Not evaluable   \n",
       " 79                Progression         Stable disease   \n",
       " 82                Progression  Physician assessed PD   \n",
       " 83                Progression  Physician assessed PD   \n",
       " 85                      Death          Not evaluable   \n",
       " 92                   Toxicity  Physician Assessed SD   \n",
       " 97                Progression  Physician assessed SD   \n",
       " \n",
       "     Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 0                                  45  ...        1  \\\n",
       " 4                                  52  ...        1   \n",
       " 6                                  57  ...        1   \n",
       " 9                                  41  ...        1   \n",
       " 18                                 32  ...        1   \n",
       " 20                                 72  ...        1   \n",
       " 23                                 61  ...        0   \n",
       " 25                                 66  ...        1   \n",
       " 26                                 59  ...        1   \n",
       " 28                                 47  ...        1   \n",
       " 40                                 58  ...        1   \n",
       " 41                                 64  ...        1   \n",
       " 43                                 69  ...        1   \n",
       " 51                                 65  ...        1   \n",
       " 52                                 60  ...        1   \n",
       " 53                                 51  ...        1   \n",
       " 61                                 45  ...        1   \n",
       " 71                                 64  ...        1   \n",
       " 72                                 62  ...        1   \n",
       " 79                                 28  ...        1   \n",
       " 82                                 45  ...        1   \n",
       " 83                                 52  ...        1   \n",
       " 85                                 67  ...        1   \n",
       " 92                                 60  ...        1   \n",
       " 97                                 50  ...        0   \n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 0                          179              1               NCB  \\\n",
       " 4                           80              1               NCB   \n",
       " 6                          130              1               NCB   \n",
       " 9                           70              0               NCB   \n",
       " 18                         125              1               NCB   \n",
       " 20                         102              1               NCB   \n",
       " 23                         557              1               DCB   \n",
       " 25                         188              1               DCB   \n",
       " 26                          29              1               NCB   \n",
       " 28                          32              1               NCB   \n",
       " 40                         503              1               DCB   \n",
       " 41                         340              0               DCB   \n",
       " 43                          95              1               NCB   \n",
       " 51                         170              1               NCB   \n",
       " 52                          10              1               NCB   \n",
       " 53                         769              0               DCB   \n",
       " 61                          54              1               NCB   \n",
       " 71                          95              1               NCB   \n",
       " 72                          54              0               NCB   \n",
       " 79                         122              1               NCB   \n",
       " 82                          55              1               NCB   \n",
       " 83                          76              1               NCB   \n",
       " 85                          13              0               NCB   \n",
       " 92                         401              0               DCB   \n",
       " 97                         104              1               NCB   \n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 0           0.351869         11.095310            23.0729            4.1689  \\\n",
       " 4           0.009323          4.606660             7.1503            1.8234   \n",
       " 6           0.351194          1.432559             2.0742            9.6682   \n",
       " 9           0.038359          5.477431             3.1350            0.4835   \n",
       " 18          0.042943          6.488650             6.8009            1.5394   \n",
       " 20          0.483515          1.376380             1.4563           17.1535   \n",
       " 23          0.173110          1.095486             1.0423            1.1816   \n",
       " 25          0.054904         12.724495            23.2112            1.1874   \n",
       " 26          0.162738          2.640403             3.9165           17.1954   \n",
       " 28          0.011377         11.179578            18.6991            3.1240   \n",
       " 40          0.001527         22.387246            37.0188            2.9120   \n",
       " 41          0.237024          1.264023             4.1110           31.4009   \n",
       " 43          0.043570          9.887466            17.4565            6.9208   \n",
       " 51          0.092849         11.376204            20.2500            1.7913   \n",
       " 52          0.140440         47.414894            60.9330            1.9185   \n",
       " 53          0.066979          9.297589            18.4017           21.9934   \n",
       " 61          0.107954          2.022436             2.1248            2.4308   \n",
       " 71          0.044343          2.949386             4.4516            2.4280   \n",
       " 72          0.042300          4.662839             6.7988            0.5133   \n",
       " 79          0.029550          4.297677             6.2113            4.6972   \n",
       " 82          0.000000          2.219062             2.8882            2.5904   \n",
       " 83          0.065723          4.072962             6.9433            0.8418   \n",
       " 85          0.001052          2.219062             2.6721            3.4181   \n",
       " 92          0.695396         84.998501            96.4079            8.4768   \n",
       " 97          0.110416         33.763449            53.2769           23.8818   \n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 0          55.51575  Non-lymph related  \n",
       " 4          38.42695  Non-lymph related  \n",
       " 6         110.18996  Non-lymph related  \n",
       " 9           6.76743  Non-lymph related  \n",
       " 18          6.75839  Non-lymph related  \n",
       " 20         80.26835  Non-lymph related  \n",
       " 23         14.09756  Non-lymph related  \n",
       " 25          7.55635      Lymph related  \n",
       " 26         11.07861  Non-lymph related  \n",
       " 28          2.04469  Non-lymph related  \n",
       " 40          9.01973  Non-lymph related  \n",
       " 41         44.31068      Lymph related  \n",
       " 43         53.73068  Non-lymph related  \n",
       " 51          5.79991  Non-lymph related  \n",
       " 52          6.50886      Lymph related  \n",
       " 53         35.96894  Non-lymph related  \n",
       " 61         15.09254      Lymph related  \n",
       " 71          8.51176  Non-lymph related  \n",
       " 72          2.46671  Non-lymph related  \n",
       " 79         15.43289  Non-lymph related  \n",
       " 82          3.16551  Non-lymph related  \n",
       " 83          4.43897  Non-lymph related  \n",
       " 85          1.79181  Non-lymph related  \n",
       " 92         86.62561  Non-lymph related  \n",
       " 97         11.22022  Non-lymph related  \n",
       " \n",
       " [25 rows x 21 columns],\n",
       " 'LYMP':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 57         31979  EGAD00001003724        LYMP   M               5  \\\n",
       " \n",
       "                                 Immunotherapy regimen Cohort   \n",
       " 57  NIVOLUMAB (P1T986205),BMS-986205 (P1T986205)/I...  Naive  \\\n",
       " \n",
       "    Reason for discontinuation        Best response   \n",
       " 57                Progression  Progressive disease  \\\n",
       " \n",
       "     Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 57                                 61  ...        1  \\\n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 57                          43              1               NCB  \\\n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 57          1.382514         43.032949            47.8654           24.7653  \\\n",
       " \n",
       "     M1M2 expression  Lymph related  \n",
       " 57        368.92979  Lymph related  \n",
       " \n",
       " [1 rows x 21 columns],\n",
       " 'OV':    Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 2         21392  EGAD00001002544          OV   F               6  \\\n",
       " \n",
       "   Immunotherapy regimen Cohort Reason for discontinuation   \n",
       " 2           Monalizumab  Naive                Progression  \\\n",
       " \n",
       "            Best response  Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 2  Physician assessed SD                                 57  ...        1  \\\n",
       " \n",
       "    Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 2                          79              1               NCB  \\\n",
       " \n",
       "   CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 2          0.040394          2.415688             4.1274            4.0377  \\\n",
       " \n",
       "    M1M2 expression  Lymph related  \n",
       " 2         50.12008  Lymph related  \n",
       " \n",
       " [1 rows x 21 columns],\n",
       " 'PANC':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 15         24363  EGAD00001002597        PANC   F               4  \\\n",
       " 38         28212  EGAD00001003073        PANC   F               2   \n",
       " \n",
       "    Immunotherapy regimen Cohort Reason for discontinuation   \n",
       " 15             Nivolumab  Naive                Progression  \\\n",
       " 38            Durvalumab  Naive                Progression   \n",
       " \n",
       "             Best response  Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 15  Physician assessed PD                                 46  ...        1  \\\n",
       " 38    Progressive disease                                 51  ...        1   \n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 15                          38              1               NCB  \\\n",
       " 38                          42              1               NCB   \n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 15          0.034957          3.454995             4.3532            0.9012  \\\n",
       " 38          0.021160          1.938168             2.4923            1.1512   \n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 15          2.06238  Non-lymph related  \n",
       " 38          2.74189  Non-lymph related  \n",
       " \n",
       " [2 rows x 21 columns],\n",
       " 'SARC':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 12         23764  EGAD00001002583        SARC   M               5  \\\n",
       " 14         24294  EGAD00001002593        SARC   M               3   \n",
       " 31         27025  EGAD00001003024        SARC   M               2   \n",
       " 36         27981  EGAD00001003062        SARC   F               5   \n",
       " 68         33988  EGAD00001004628        SARC   M               3   \n",
       " \n",
       "        Immunotherapy regimen Cohort Reason for discontinuation   \n",
       " 12              Atezolizumab  Naive                Progression  \\\n",
       " 14              Atezolizumab  Naive                Progression   \n",
       " 31              Atezolizumab  Naive                Progression   \n",
       " 36             Pembrolizumab  Naive                Progression   \n",
       " 68  Tremelimumab, Durvalumab  Naive                Progression   \n",
       " \n",
       "             Best response  Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 12         Stable disease                                 59  ...        1  \\\n",
       " 14    Progressive disease                                 56  ...        1   \n",
       " 31    Progressive disease                                 44  ...        0   \n",
       " 36  Physician assessed PD                                 26  ...        1   \n",
       " 68    Progressive disease                                 50  ...        1   \n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 12                         222              1               DCB  \\\n",
       " 14                          81              1               NCB   \n",
       " 31                          85              1               NCB   \n",
       " 36                          86              1               NCB   \n",
       " 68                          35              1               NCB   \n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 12          0.262311          1.404470             2.7140            3.1427  \\\n",
       " 14          0.001192          1.207844             2.0539            0.3580   \n",
       " 31          0.337149          1.825810             2.0019            1.3691   \n",
       " 36          0.000000          2.668492             3.7008            0.0291   \n",
       " 68          0.017089          3.707800             4.6956            0.6140   \n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 12        467.93886  Non-lymph related  \n",
       " 14          0.84480  Non-lymph related  \n",
       " 31         13.87632  Non-lymph related  \n",
       " 36          0.24924  Non-lymph related  \n",
       " 68          3.13421  Non-lymph related  \n",
       " \n",
       " [5 rows x 21 columns],\n",
       " 'SKCM':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 3          21516  EGAD00001002546        SKCM   F               3  \\\n",
       " 13         23808  EGAD00001002585        SKCM   F               5   \n",
       " 39         28224  EGAD00001003603        SKCM   M               1   \n",
       " 74         36063  EGAD00001004653        SKCM   M               1   \n",
       " 88         38599  EGAD00001004917        SKCM   M               1   \n",
       " 89         38947  EGAD00001004931        SKCM   F               1   \n",
       " 90         37013  EGAD00001005831        SKCM   F               3   \n",
       " \n",
       "                                 Immunotherapy regimen Cohort   \n",
       " 3                                          Ipilimumab  Naive  \\\n",
       " 13                                      Pembrolizumab  Naive   \n",
       " 39                                          Nivolumab  Naive   \n",
       " 74       NIVOLUMAB (P1T986205),BMS-986205 (P1T986205)  Naive   \n",
       " 88  NIVOLUMAB (P1T986205),BMS-986205 (P1T986205)/I...  Naive   \n",
       " 89                                      Pembrolizumab  Naive   \n",
       " 90  NIVOLUMAB (P1T986205),BMS-986205 (P1T986205)/I...  Naive   \n",
       " \n",
       "    Reason for discontinuation           Best response   \n",
       " 3                       Death           Not evaluable  \\\n",
       " 13                    Ongoing   Physician assessed SD   \n",
       " 39             Patient choice   Physician assessed PR   \n",
       " 74                Progression     Progressive disease   \n",
       " 88                Progression  Physician assessed PD    \n",
       " 89                Progression   Physician assessed SD   \n",
       " 90                    Ongoing        Partial Response   \n",
       " \n",
       "     Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 3                                  29  ...        1  \\\n",
       " 13                                 66  ...        0   \n",
       " 39                                 48  ...        0   \n",
       " 74                                 57  ...        1   \n",
       " 88                                 71  ...        0   \n",
       " 89                                 47  ...        1   \n",
       " 90                                 70  ...        0   \n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 3                           11              0               NCB  \\\n",
       " 13                         578              0               DCB   \n",
       " 39                         535              1               DCB   \n",
       " 74                          43              1               NCB   \n",
       " 88                          53              1               NCB   \n",
       " 89                         141              1               NCB   \n",
       " 90                         544              0               DCB   \n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 3           0.052774          6.235845            11.4871            0.6006  \\\n",
       " 13          0.060953         17.612049            33.6950            0.2410   \n",
       " 39          0.010180         23.875983            40.1297            0.3657   \n",
       " 74          0.035548          8.482996            14.0202            1.2579   \n",
       " 88          0.721065         67.161737           100.6487            4.4703   \n",
       " 89          0.008531         19.887290            29.7956            0.8520   \n",
       " 90          0.104139         38.735272            64.3748           31.8002   \n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 3           1.58550  Non-lymph related  \n",
       " 13          5.25660  Non-lymph related  \n",
       " 39          1.39105      Lymph related  \n",
       " 74          5.42335  Non-lymph related  \n",
       " 88         18.01896  Non-lymph related  \n",
       " 89          3.56523      Lymph related  \n",
       " 90         11.20933      Lymph related  \n",
       " \n",
       " [7 rows x 21 columns],\n",
       " 'STAD':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 27         26125  EGAD00001003013        STAD   F               3  \\\n",
       " 69         33740  EGAD00001004625        STAD   M               4   \n",
       " \n",
       "                                 Immunotherapy regimen Cohort   \n",
       " 27  PEMBROLIZUMAB (SELF PAY) then NIVOLUMAB (SELF ...  Naive  \\\n",
       " 69                                          Nivolumab  Naive   \n",
       " \n",
       "    Reason for discontinuation          Best response   \n",
       " 27                Progression  Physician assessed SD  \\\n",
       " 69                Progression  Physician assessed PD   \n",
       " \n",
       "     Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 27                                 48  ...        1  \\\n",
       " 69                                 71  ...        1   \n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 27                         290              1               DCB  \\\n",
       " 69                          34              1               NCB   \n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 27           0.01285          2.668492             4.4817            0.8840  \\\n",
       " 69           0.08086          4.072962             7.2868            0.4938   \n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 27          3.77268  Non-lymph related  \n",
       " 69          2.59044  Non-lymph related  \n",
       " \n",
       " [2 rows x 21 columns],\n",
       " 'THYM':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 17         25559  EGAD00001002614        THYM   M               3  \\\n",
       " \n",
       "    Immunotherapy regimen Cohort Reason for discontinuation     Best response   \n",
       " 17          Atezolizumab  Naive                    Ongoing  Partial response  \\\n",
       " \n",
       "     Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 17                                 25  ...        0  \\\n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 17                         756              0               DCB  \\\n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 17           0.68093           0.92695             1.3296            27.371  \\\n",
       " \n",
       "     M1M2 expression  Lymph related  \n",
       " 17         98.38025  Lymph related  \n",
       " \n",
       " [1 rows x 21 columns],\n",
       " 'UCEC':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 22         25603  EGAD00001002631        UCEC   F               3  \\\n",
       " 35         27792  EGAD00001003059        UCEC   F               4   \n",
       " 65         34211  EGAD00001004636        UCEC   F               4   \n",
       " \n",
       "                                 Immunotherapy regimen Cohort   \n",
       " 22              Nivolumab +IDO1 inhibitor (BMS986205)  Naive  \\\n",
       " 35                                        Monalizumab  Naive   \n",
       " 65  NIVOLUMAB (P1T986205),BMS-986205 (P1T986205)/I...  Naive   \n",
       " \n",
       "    Reason for discontinuation        Best response   \n",
       " 22                Progression  Progressive disease  \\\n",
       " 35                Progression  Progressive disease   \n",
       " 65                Progression  Progressive disease   \n",
       " \n",
       "     Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 22                                 66  ...        1  \\\n",
       " 35                                 56  ...        1   \n",
       " 65                                 39  ...        1   \n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 22                          71              1               NCB  \\\n",
       " 35                          51              1               NCB   \n",
       " 65                          38              1               NCB   \n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 22          0.056103          9.185231             6.4734            0.5335  \\\n",
       " 35          0.020193          1.881989             2.8383            2.0192   \n",
       " 65          0.030412          4.129141             4.8210            1.6066   \n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 22         12.05872      Lymph related  \n",
       " 35         20.98266  Non-lymph related  \n",
       " 65          7.63033  Non-lymph related  \n",
       " \n",
       " [3 rows x 21 columns],\n",
       " 'UVM':     Anonymous ID           EGA ID Tumour type Sex Line of therapy   \n",
       " 62         32667  EGAD00001004605         UVM   F               1  \\\n",
       " 75         35290  EGAD00001004647         UVM   M               1   \n",
       " \n",
       "    Immunotherapy regimen Cohort Reason for discontinuation   \n",
       " 62         Pembrolizumab  Naive                Progression  \\\n",
       " 75         Pembrolizumab  Naive                Progression   \n",
       " \n",
       "             Best response  Age at advanced disease diagnosis  ...  Alive_0   \n",
       " 62  Physician assessed PD                                 58  ...        1  \\\n",
       " 75  Physician assessed PD                                 86  ...        1   \n",
       " \n",
       "     Time to progression (days)  Progression_1  Clinical benefit   \n",
       " 62                          97              1               NCB  \\\n",
       " 75                         137              1               NCB   \n",
       " \n",
       "    CD8+ T cell score  Exome mut per mb  Genome mut per mb  CD274 expression   \n",
       " 62          0.040777          2.050526             1.8483            0.7770  \\\n",
       " 75          0.050551          1.095486             1.5425            0.7701   \n",
       " \n",
       "     M1M2 expression      Lymph related  \n",
       " 62          3.94478  Non-lymph related  \n",
       " 75          4.12850  Non-lymph related  \n",
       " \n",
       " [2 rows x 21 columns]}"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "dico_tumour"
   ]
  },
  {
   "attachments": {},
   "cell_type": "markdown",
   "metadata": {},
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.6"
  },
  "orig_nbformat": 4
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
